Cleerly
Cleerly Company Growth, Stability & Outlook in Colorado Springs
This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Cleerly and has not been reviewed or approved by Cleerly.
What's the stability & growth outlook for Cleerly?
Strengths in capital access, reimbursement traction, and ecosystem partnerships are balanced by a competitive landscape and execution frictions around payer criteria and workflow adoption. Together, these dynamics suggest Cleerly is in a commercial expansion phase with solid enablers, while share capture and pricing will hinge on navigating rival offerings, IP risk, and operational scaling.
Key Insight for Candidates
Reimbursement- and FDA-driven commercialization surge defines the office: after Category I CPT 75577 and new clearance, Cleerly is scaling fast. In Colorado Springs, expect focus on operationalizing payer policies, workflow integrations, and health‑system rollouts—high momentum with evolving processes and visible market impact.Evidence in Action
- Reimbursement-Anchored Growth Planning — Category I CPT 75577, effective January 1, 2026, plus UnitedHealthcare, Cigna, and Aetna coverage and UHC prior-authorization references, define Cleerly’s reimbursement pathway. Colorado Springs teams plan adoption and billing workflows with greater predictability, reducing friction for local provider rollout.
- Capital-Backed Scaling Cadence — A $223M Series C in 2022 and a $106M Series C-II on December 4, 2024 provide fuel for commercialization and R&D. Colorado Springs employees operate with clearer runway and resources to scale deployments, evidence generation, and partnerships.
Positive Themes About Cleerly
-
Investor Backing & Capital Strength: Recent late‑stage financings, including a Series C extension in late 2024 on top of a large 2022 round, provide significant capital to scale commercialization and evidence generation. This funding base supports continued R&D and market rollout.
-
Strong Market Position & Advantage: Regulatory and reimbursement momentum—FDA 510(k) clearance in 2025 and a permanent Category I CPT code (75577) effective 2026 with major payer coverage—reduces adoption friction and broadens access. Health‑system deployments and workflow integrations signal strengthening clinical embedment.
-
Strategic Partnerships: Partnerships with Cardiac Care Alliance, OEM/channel ties (e.g., Canon), and workflow integrations (e.g., PowerScribe) expand reach and ease provider uptake. New collaborations and site rollouts (e.g., MemorialCare) point to an enlarging commercial ecosystem.
Considerations About Cleerly
-
Weak Market Position & Pricing Challenges: Category I CPT 75577 is accessible to rivals, and competitors (e.g., HeartFlow, Circle CVI, Elucid) now market FDA‑cleared plaque analysis, which can pressure pricing and share even as the category expands. An active IP lawsuit underscores the contested nature of the space.
-
Operational Inefficiency: Coverage remains heterogeneous with prior‑authorization criteria and documentation variability across plans, and hospitals face validation, integration, and training hurdles—factors that can slow real‑world scaling. These execution demands may delay utilization relative to policy wins.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
Cleerly FAQs
Is This Your Company?
Claim Profile
